Total Payments
$4,748
2024 Payments
$38.35
Companies
10
Transactions
26
Medicare Patients
989
Medicare Billing
$217,478
Payment Breakdown by Category
Consulting$2,800 (59.0%)
Travel$692.02 (14.6%)
Research$676.98 (14.3%)
Food & Beverage$571.87 (12.0%)
Education$6.81 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,800 | 1 | 59.0% |
| Travel and Lodging | $692.02 | 3 | 14.6% |
| Unspecified | $676.98 | 5 | 14.3% |
| Food and Beverage | $571.87 | 16 | 12.0% |
| Education | $6.81 | 1 | 0.1% |
Payments by Type
General
$4,071
21 transactions
Research
$676.98
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,966 | 3 | $0 (2021) |
| Intuitive Surgical, Inc. | $872.80 | 6 | $0 (2023) |
| F. Hoffmann-La Roche AG | $460.98 | 2 | $0 (2021) |
| TESARO, Inc. | $222.81 | 4 | $0 (2017) |
| Myriad Genetic Laboratories, Inc. | $109.74 | 4 | $0 (2023) |
| PFIZER INC. | $45.53 | 3 | $0 (2019) |
| Dexcom, Inc. | $22.50 | 1 | $0 (2024) |
| ImmunoGen, Inc. | $16.81 | 1 | $0 (2023) |
| ABBVIE INC. | $15.85 | 1 | $0 (2024) |
| Clovis Oncology, Inc. | $15.04 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38.35 | 2 | Dexcom, Inc. ($22.50) |
| 2023 | $135.90 | 6 | Myriad Genetic Laboratories, Inc. ($109.74) |
| 2021 | $547.87 | 3 | F. Hoffmann-La Roche AG ($460.98) |
| 2020 | $15.04 | 1 | Clovis Oncology, Inc. ($15.04) |
| 2019 | $2,895 | 3 | AstraZeneca Pharmaceuticals LP ($2,879) |
| 2018 | $822.49 | 5 | Intuitive Surgical, Inc. ($806.69) |
| 2017 | $293.25 | 6 | TESARO, Inc. ($222.81) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/13/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Endocrinology | ||||||
| 02/22/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2023 | ImmunoGen, Inc. | Elahere (Biological) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Oncology | ||||||
| 10/17/2023 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $60.96 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2023 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2023 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: ONCOLOGY | ||||||
| 03/27/2023 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: ONCOLOGY | ||||||
| 01/03/2023 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $9.35 | General |
| Category: SURGERY | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $254.13 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $206.85 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
| 03/11/2021 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $86.89 | General |
| 09/09/2020 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: Oncology | ||||||
| 05/13/2019 | PFIZER INC. | IBRANCE (Drug), TALZENNA | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: ONCOLOGY | ||||||
| 03/20/2019 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Oncology | ||||||
| 03/19/2019 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $78.73 | General |
| Category: Oncology | ||||||
| 06/04/2018 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2018 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $114.67 | General |
| Category: SURGERY | ||||||
| 01/25/2018 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $252.42 | General |
| Category: SURGERY | ||||||
| 01/12/2018 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $408.60 | General |
| Category: SURGERY | ||||||
| 01/12/2018 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $31.00 | General |
| Category: SURGERY | ||||||
| 08/15/2017 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $56.76 | General |
| Category: SURGERY | ||||||
| 04/10/2017 | TESARO, Inc. | ZEJULA (Drug) | Education | In-kind items and services | $6.81 | General |
| Category: ONCOLOGY | ||||||
| 04/05/2017 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $48.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 04/05/2017 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $18.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 04/01/2017 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER | F. Hoffmann-La Roche AG | $460.98 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | TESARO, Inc. | $216.00 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 226 | 414 | $165,529 | $58,450 |
| 2022 | 9 | 241 | 395 | $166,948 | $58,361 |
| 2021 | 9 | 222 | 326 | $110,841 | $40,835 |
| 2020 | 7 | 300 | 507 | $191,016 | $59,832 |
Total Patients
989
Total Services
1,642
Medicare Billing
$217,478
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 54 | 216 | $80,455 | $29,425 | 36.6% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2023 | 14 | 14 | $26,670 | $10,048 | 37.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 44 | 44 | $23,206 | $7,241 | 31.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 58 | $15,559 | $5,373 | 34.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 18 | 21 | $7,040 | $2,146 | 30.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 27 | $4,968 | $1,776 | 35.8% |
| 38900 | Imaging of lymph nodes during surgery | Facility | 2023 | 16 | 16 | $5,904 | $1,738 | 29.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 11 | 18 | $1,727 | $703.80 | 40.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 43 | 167 | $58,982 | $22,322 | 37.8% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2022 | 20 | 20 | $35,253 | $13,945 | 39.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 55 | 79 | $20,335 | $7,139 | 35.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 21 | 21 | $10,546 | $3,555 | 33.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 26 | 26 | $10,397 | $3,390 | 32.6% |
| 38571 | Removal of lymph nodes of both sides of pelvis using an endoscope | Facility | 2022 | 12 | 12 | $17,052 | $3,157 | 18.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 35 | 40 | $7,025 | $2,511 | 35.7% |
| 38900 | Imaging of lymph nodes during surgery | Facility | 2022 | 17 | 17 | $5,967 | $1,902 | 31.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 12 | 13 | $1,391 | $438.78 | 31.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 41 | 105 | $37,485 | $14,371 | 38.3% |
| 58571 | Abdominal removal of uterus (250 grams or less) with removal of tubes and/or ovaries using an endoscope | Facility | 2021 | 15 | 15 | $27,210 | $9,756 | 35.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 49 | 75 | $18,930 | $7,186 | 38.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 35 | 39 | $6,567 | $2,390 | 36.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 14 | 14 | $7,154 | $2,300 | 32.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 18 | 18 | $7,142 | $2,239 | 31.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 21 | 28 | $3,373 | $1,594 | 47.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 17 | 20 | $2,140 | $836.19 | 39.1% |
About Dr. Thomas Reid, MD
Dr. Thomas Reid, MD is a Obstetrics & Gynecology healthcare provider based in Dayton, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245296409.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Reid, MD has received a total of $4,748 in payments from pharmaceutical and medical device companies, with $38.35 received in 2024. These payments were reported across 26 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($2,800).
As a Medicare-enrolled provider, Reid has provided services to 989 Medicare beneficiaries, totaling 1,642 services with total Medicare billing of $217,478. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Obstetrics & Gynecology
- Other Specialties Gynecologic Oncology
- Location Dayton, OH
- Active Since 04/25/2006
- Last Updated 10/30/2024
- Taxonomy Code 207V00000X
- Entity Type Individual
- NPI Number 1245296409
Products in Payments
- LYNPARZA (Drug) $2,879
- Da Vinci Surgical System (Device) $872.80
- TECENTRIQ (Biological) $460.98
- ZEJULA (Drug) $222.81
- MYRISK (Device) $109.74
- IBRANCE (Drug) $45.53
- Dexcom G6 Transmitter (Medical Supply) $22.50
- Elahere (Biological) $16.81
- ELAHERE (Drug) $15.85
- Rubraca (Drug) $15.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Obstetrics & Gynecology Doctors in Dayton
Caroline Kennebeck, M.d, M.D
Obstetrics & Gynecology — Payments: $12,169
Obstetrics & Gynecology $12,169
John Shie, M.d, M.D
Obstetrics & Gynecology — Payments: $9,835
Obstetrics & Gynecology $9,835
Dr. Kelly Mccluskey-Erskine, M.d, M.D
Obstetrics & Gynecology — Payments: $9,580
Obstetrics & Gynecology $9,580
Mrs. Shannon Mcafee, D.o, D.O
Obstetrics & Gynecology — Payments: $9,337
Obstetrics & Gynecology $9,337
Percy Frasier, M.d, M.D
Obstetrics & Gynecology — Payments: $6,878
Obstetrics & Gynecology $6,878
Cooper Trost, Do, DO
Obstetrics & Gynecology — Payments: $4,495
Obstetrics & Gynecology $4,495